Medicine Details
Brand name – Hepcvir L
Generic name – Sofosbuvir/Ledipasvir
Manufacturer – Cipla Ltd.
Salt composition – Ledipasvir (90mg) + Sofosbuvir (400mg)
Storage – Store at room temperature (10-30°C)
Dosage form – Oral (tablet)
Strength – 90mg/400mg
Packaging – Bottle of 28 tablets
Gender – Unisex
Prescription required – Yes
Indication – used in the treatment of Chronic hepatitis C virus (HCV) infection
Description
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is a combination of two antiviral medications, used in the treatment of chronic (long-lasting) hepatitis C virus (HCV) infection in adults. It is a fixed-dose combination of Ledipasvir and Sofosbuvir. Ledipasvir and Sofosbuvir are the direct-acting antiviral medications. It is an antiviral medicine that works to lower the multiplication of viruses in the body and eliminates the virus from the body over a period of time.
Pharmacodynamics
Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug, that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
Thorough QT studies have been conducted for Sofosbuvir/Ledipasvir. The effect of Ledipasvir 120 mg twice daily (2.67 times the maximum recommended dosage) for 10 days on QTc interval was calculated in a randomized, multiple-dose, placebo- and active-controlled (moxifloxacin 400 mg), three-period, crossover thorough QT trial in 59 healthy subjects. At the dose of 120 mg twice daily (2.67 times the maximum recommended dosage), Ledipasvir does not prolong QTc interval to any clinically relevant extent. The effect of Sofosbuvir 400 mg (maximum recommended dosage) and 1,200 mg (three times the maximum recommended dosage) on QTc interval was calculated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg), four-period, crossover thorough QT trial in 59 healthy subjects. At a dose three times the maximum recommended dose, Sofosbuvir does not prolong QTc to any clinically relevant extent.
Ingredients
The active ingredient of Hepcvir L is Sofosbuvir/Ledipasvir.
Usage Of Medicine
Hepcvir L (Sofosbuvir 400mg and Ledipasvir 90mg) is used in the treatment of Chronic hepatitis C virus (HCV) infection.


